Ravindranath Kolli, MD
Psychiatry · Monessen, PANPI 1093709040
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,531 of the $119,003 with a category attached, or 87.0%. AbbVie accounts for 71.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $22,126 and has fallen 53.0% since, to $10,401 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $241.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Otsuka America Pharmaceutical, Inc.$29K
- Pfizer$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$556
- Teva Pharmaceuticals USA, Inc.$556
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$103,53187%
- Travel & lodging$7,4066%
- Food & beverage$7,9567%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 213 | $84,701 |
| Otsuka America Pharmaceutical, Inc. | 113 | $28,530 |
| Pfizer | 4 | $1,556 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $1,411 |
| Vanda Pharmaceuticals Inc. | 27 | $556 |
| Teva Pharmaceuticals USA, Inc. | 24 | $556 |
| Alkermes, Inc. | 31 | $460 |
| Johnson & Johnson | 23 | $450 |
| Neurocrine Biosciences, Inc. | 30 | $401 |
| Indivior Inc. | 8 | $148 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Lundbeck LLC | 2 | $34 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Almatica Pharma LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$81,384
- ABILIFY MAINTENA$26,747
- ABILIFY ASIMTUFII$8,186
- CAPLYTA$1,350
- REXULTI$264
How this compares
$119,003 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 406 | $1,375,173 |
| Abilify MaintenaAripiprazole | 60 | $176,685 |
| VraylarCariprazine Hcl | 114 | $157,673 |
| Invega TrinzaPaliperidone Palmitate | 16 | $115,145 |
| IngrezzaValbenazine Tosylate | 12 | $94,133 |
| UzedyRisperidone | 28 | $86,653 |
| Clozapine | 434 | $25,551 |
| Divalproex Sodium ErDivalproex Sodium | 295 | $15,583 |
| TrintellixVortioxetine Hydrobromide | 29 | $13,700 |
| Modafinil | 12 | $7,811 |
| Chlorpromazine Hcl | 40 | $7,747 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 44 | $7,685 |
| Lurasidone Hcl | 52 | $5,376 |
| Benztropine Mesylate | 522 | $5,025 |
| Quetiapine Fumarate | 435 | $4,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $450 | $1,490,317422 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $28,530 | $176,68560 claims |
| AbbVieVraylar | $84,701 | $157,673114 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $401 | $94,13312 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $556 | $86,65328 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $16 | $13,70029 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $1,703190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Monessen
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.